Overview
By uniquely bringing Patient Selection into the Target Identification stage.
Approach
Using real patients data, we integrate target identification with cohort selection into a single coherent strategy.
We use 100% of Genome Data, both Exome & Dark Genome alterations. With a wealth of patient-derived tumor data, we can identify novel drug targets “invisible” in cell line-based assays.
Gordion Bioscience Inc., 245 Main St, Cambridge, MA 02142, US
#J-18808-Ljbffr